Rapid versus conventional initiation of quetiapine in the treatment of schizophrenia: A randomized, parallel-group trial

Journal of Clinical Psychiatry

Volumn 68, Issue 3, 2007, Pages 399-405

  Pae, Chi Un ^a,b,e   Kim, Jung Jin ^a   Lee, Chang Uk ^a   Lee, Soo Jung ^a   Lee, Chul ^a   Patkar, Ashwin A ^b,c   Masand, Prakash S ^b,d   Paik, In Ho ^a  

^a The Catholic University of Korea   (South Korea)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

^e The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE; BENZATROPINE MESILATE; LORAZEPAM; QUETIAPINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HEADACHE; HUMAN; ORTHOSTATIC HYPOTENSION; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESTLESSNESS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; TREMOR; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

EID: 33947722538     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v68n0307     Document Type: Article

References (32)

1. Arango C, Bobes I. Managing acute exacerbations of schizophrenia: focus on quetiapine. Curr Med Res Opin 2004;20:619-626
2. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia, revised 2004. Available at: www.psych.org. Accessed August 15, 2005
3. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Report 1962;10:799-812
4. CGI Clinical Global Impressions. In: Guy W, Bonato RR, eds. Manual for the ECDEU Assessment Battery, 2. Rev Ed. Chevy Chase, Md: National Institute of Mental Health; 1962:217-222
5. Arvanitis LA, Miller BG, the Seroquel Trial 13 study group. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-246
6. Borison RL, Arvanitis LA, Miller BG, et al. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996;16: 158-169
7. Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997;54:549-557
8. Small JG, Kolar MC, Kellams JJ. Quetiapine in schizophrenia: onset of action within the first week of treatment. Curr Med Res Opin 2004;20: 1017-1023
9. Peuskens J, Link CGG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997;96: 265-273
10. Ganesan S, Levy M, Bilsker D, et al. Effectiveness of quetiapine for the management of aggressive psychosis in the emergency psychiatric setting: a naturalistic uncontrolled trial. Int J Psychiatr Clin Pract 2005;9: 199-203
11. Meats P. Quetiapine ('Seroquel'): an effective and well-tolerated atypical antipsychotic. Int J Psychiatry Clin Pract 1997;1:231-239
12. Arvanitis LA, Rak IW. The long-term efficacy and safety of 'Seroquel' (Quetiapine) [poster]. Presented at the International Congress on Schizophrenia Research; April 12-16, 1997; Colorado Springs, Co
13. Zhong X, Sweitzer D, Hamer RM, et al. Comparison of quetiapine and risperidone in the treatment of schizophrenia: a randomized, double-blind, flexible-dose, 8-week study. J Clin Psychiatry 2006;67:1093-1103
14. Eli Lilly and Company. Zyprexa olanzapine tablets/US prescribing information, revised 2005. Available at: http://pi.lilly.com/us/zyprexa-pi.pdf. Accessibility verified November 15, 2006
15. Daniel DG, Zimbroff DL, Pofkin SG, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology 1999;20:491-505
16. Finn SE, Bailey JM, Schultz RT, et al. Subjective utility ratings of neuroleptics in treating schizophrenia. Psychol Med 1990;20:843-848
17. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156: 1686-1696
18. Brecher M, Zukin S, Leong R, et al. Long-term weight change with quetiapine treatment in schizophrenia: a comprehensive data review. Neuropsychopharmacology 2004;29:S109
19. AstraZeneca. Seroquel (quetiapine fumarate) tablets/US prescribing information, revised 2005. Available at: http://www.astrazeneca-us.com/ pi/Seroquel.pdf. Accessibility verified November 15, 2006
20. Goldstein JM. Mechanism of action of quetiapine: modulation of dopamine at the D2 receptor [poster]. Presented at the 12th Congress of the Association of European Psychiatrists; April 14-18, 2004; Geneva, Switzerland
21. First MB, Williams JB, Spitzer RL, et al. Structured Clinical Interview for DSM-IV Axis I Disorders-Clinical Version (SCID-IV). Washington, DC: American Psychiatric Press; 1997
22. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Washington, DC: American Psychiatric Association; 1994
23. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-19
24. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676
25. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276
26. Lindenmayer JP, Brown E, Baker RW, et al. An excitement subscale of the Positive and Negative Syndrome Scale. Schizophr Res 2004;68: 331-337
27. Smith MA, McCoy R, Hamer-Maansson J, et al. Rapid dose escalation with quetiapine: a pilot study. J Clin Psychopharmacol 2005;25:331-335
28. Chengappa KNR, Goldstein JM, Greenwood M, et al. A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. Clin Ther 2003;25:530-541
29. Buckley PF. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials. Curr Med Res Opin 2004;20:1357-1363
30. Baker RW, Kinon BJ, Maguire GA, et al. Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation. J Clin Psychopharmacol 2003;23:342-348
31. Tandon R, Jibson MD. Comparing efficacy of first-line atypical antipsychotics: no evidence of differential efficacy between risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole. Int J Psychiatry Clin Pract 2005;7:204-212
32. De Nayer A, Windhager E, Irmansyah, et al. Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other antipsychotics. Int J Psychiatry Clin Pract 2003;7:59-66